IL23A and psoriasis: Further, in a clinical trial of an IL-23-specific monoclonal antibody, there was no effect on IFNG expression in patients with psoriasis despite a complete clinical and histologic response, in contrast to the significant reduction in IL17 messenger RNA levels observed [83].